Related Experiment Video
Updated: Aug 27, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Par-4 for molecular therapy of prostate cancer
James Butler1, Vivek M Rangnekar
1Department of Microbiology, University of Kentucky, Lexington, KY 40536, USA.
Abstract:
Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer deaths in American men. Although many treatment measures such as androgen deprivation, radiation therapy, and cryoablation exist for primary prostate cancer, there is currently no effective treatment for patients presenting advanced or metastatic stages of the disease. Molecular therapy offers an attractive approach to the treatment of primary prostate cancer because the prostate is not a life-sustaining organ, and a number of tissue specific promoters can be used for prostatic gene expression following relatively straightforward delivery routes. This review discusses the general molecular therapy applications in the context of prostate cancer, and most importantly, identifies the prostate apoptosis response-4 (Par-4) gene, which exclusively induces apoptosis in cancer cells and not normal cells, as a prospective molecule for therapy of the disease.
Insights
Prostate cancer is a common cancer with limited treatments for advanced stages. The prostate apoptosis response-4 (Par-4) gene shows promise for molecular therapy, selectively inducing cancer cell death.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Current treatments are insufficient for advanced or metastatic prostate cancer.
- Molecular therapy presents a promising avenue for prostate cancer treatment.
Purpose of the Study:
- To review general molecular therapy applications for prostate cancer.
- To identify potential molecular targets for prostate cancer treatment.
- To highlight the prostate apoptosis response-4 (Par-4) gene as a therapeutic candidate.
Main Methods:
- Literature review of molecular therapy strategies in prostate cancer.
- Analysis of gene-specific apoptosis induction in cancer cells.
- Evaluation of tissue-specific promoters for targeted gene delivery.
Main Results:
- Molecular therapy offers targeted treatment options for prostate cancer.
- The prostate is amenable to molecular therapy due to its non-vital organ status.
- The Par-4 gene selectively induces apoptosis in prostate cancer cells, sparing normal cells.
Conclusions:
- The Par-4 gene is a highly promising candidate for targeted molecular therapy in prostate cancer.
- Selective apoptosis induction by Par-4 offers a novel therapeutic strategy.
- Further research into Par-4-based therapies could lead to effective treatments for advanced prostate cancer.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...